<?xml version="1.0" ?><PAPER><mode2 hasDoc="yes" name="S1550413113004920.tmf1" version="elsevier"/>
<TITLE>Analysis of Transcription Factors Key for Mouse Pancreatic Development Establishes NKX2-2 and MNX1 Mutations as Causes of Neonatal Diabetes in Man
</TITLE>
<ABSTRACT>

Summary
<s sid="1"><CoreSc1 advantage="None" conceptID="Mot1" novelty="None" type="Mot"/><text>Understanding transcriptional regulation of pancreatic development is required to advance current efforts in developing beta cell replacement therapies for patients with diabetes.</text></s>
<s sid="2"><CoreSc1 advantage="None" conceptID="Mot2" novelty="None" type="Mot"/><text>Current knowledge of key transcriptional regulators has predominantly come from mouse studies, with rare, naturally occurring mutations establishing their relevance in man.</text></s>
<s sid="3"><CoreSc1 advantage="None" conceptID="Goa1" novelty="None" type="Goa"/><text>This study used a combination of homozygosity analysis and Sanger sequencing in 37 consanguineous patients with permanent neonatal diabetes to search for homozygous mutations in 29 transcription factor genes important for murine pancreatic development.</text></s>
<s sid="4"><CoreSc1 advantage="None" conceptID="Goa2" novelty="None" type="Goa"/><text>We identified homozygous mutations in 7 different genes in 11 unrelated patients and show that NKX2-2 and MNX1 are etiological genes for neonatal diabetes, thus confirming their key role in development of the human pancreas.</text></s>
<s sid="5"><CoreSc1 advantage="None" conceptID="Bac1" novelty="None" type="Bac"/><text>The similar phenotype of the patients with recessive mutations and mice with inactivation of a transcription factor gene support there being common steps critical for pancreatic development and validate the use of rodent models for beta cell development.</text></s>
Graphical Abstract
Highlights
•
<s sid="6"><CoreSc1 advantage="None" conceptID="Bac2" novelty="None" type="Bac"/><text>Homozygous mutations in seven pancreatic transcription factors cause neonatal diabetes</text></s>
•
<s sid="7"><CoreSc1 advantage="None" conceptID="Bac3" novelty="None" type="Bac"/><text>Homozygous NKX2-2 and MNX1 mutations were found in five patients</text></s>
•
<s sid="8"><CoreSc1 advantage="None" conceptID="Bac4" novelty="None" type="Bac"/><text>Confirms NKX2-2 and MNX1 are critical for murine and human pancreas development</text></s>
•
<s sid="9"><CoreSc1 advantage="None" conceptID="Bac5" novelty="None" type="Bac"/><text>Similar phenotypes in mouse and man validate models for beta cell development</text></s>
<s sid="10"><CoreSc1 advantage="None" conceptID="Bac6" novelty="None" type="Bac"/><text>Analyzing a large collection of consanguineous patients with permanent neonatal diabetes, Flanagan et al. performed a comprehensive search for recessive mutations in transcription factors known to be critical for mouse pancreatic development.</text></s>
<s sid="11"><CoreSc1 advantage="None" conceptID="Bac7" novelty="None" type="Bac"/><text>They identify seven pancreatic transcription factors that cause neonatal diabetes, including NKX2-2 and MNX1.</text></s>
</ABSTRACT>
<BODY>

Introduction
<s sid="12"><CoreSc1 advantage="None" conceptID="Bac8" novelty="None" type="Bac"/><text>Knowledge on transcriptional regulators of pancreatic development and beta cell differentiation is essential for the development of beta cell replacement therapies for diabetes (Kroon et al., 2008; Zhou et al., 2008).</text></s>
<s sid="13"><CoreSc1 advantage="None" conceptID="Bac9" novelty="None" type="Bac"/><text>While major work has been undertaken in mice, the extent to which murine pancreatic development is a good model for man is not fully understood.</text></s>
<s sid="14"><CoreSc1 advantage="None" conceptID="Mot3" novelty="None" type="Mot"/><text>Finding inactivating mutations in patients with diabetes can establish the role of a gene in human pancreatic development and function.</text></s>
<s sid="15"><CoreSc1 advantage="None" conceptID="Mot4" novelty="None" type="Mot"/><text>Comparing the human phenotype with mouse models for the same gene is important, as it validates that the gene function is similar in man and mouse.</text></s>
<s sid="16"><CoreSc1 advantage="None" conceptID="Bac10" novelty="None" type="Bac"/><text>Concordant phenotypes between mouse models with biallelic gene inactivation and humans with biallelic mutations suggest similar function of the gene product in rodents and man.</text></s>
<s sid="17"><CoreSc1 advantage="None" conceptID="Bac11" novelty="None" type="Bac"/><text>For example, biallelic GCK mutations in humans cause permanent neonatal diabetes (PNDM), and mice lacking both copies of the gene have severe hyperglycemia at birth (Njølstad et al., 2001; Terauchi et al., 1995).</text></s>
<s sid="18"><CoreSc1 advantage="None" conceptID="Bac12" novelty="None" type="Bac"/><text>Both patients with recessive EIF2AK3 mutations and the Perk null mouse (Eif2ak3-/-) develop diabetes due to destruction of beta cells as a result of endoplasmic reticulum stress (Delépine et al., 2000; Harding et al., 2001; Zhang et al., 2002)</text></s>
<s sid="19"><CoreSc1 advantage="None" conceptID="Bac13" novelty="None" type="Bac"/><text>The correlation in phenotype between knockout mice and humans with recessive mutations is not always evident.</text></s>
<s sid="20"><CoreSc1 advantage="None" conceptID="Bac14" novelty="None" type="Bac"/><text>Biallelic loss-of-function ABCC8 mutations are the most common known cause of hyperinsulinemic hypoglycemia in humans, whereas ABCC8 null mice maintain euglycemia (Shiota et al., 2002; Thomas et al., 1995).</text></s>
<s sid="21"><CoreSc1 advantage="None" conceptID="Bac15" novelty="None" type="Bac"/><text>GLUT2 has been shown to be the primary glucose transporter and sensor in rodent pancreatic islets, whereas studies in humans have suggested that GLUT1 plays an important role in facilitating glucose entry into the developing beta cell (De Vos et al., 1995; McCulloch et al., 2011).</text></s>
<s sid="22"><CoreSc1 advantage="None" conceptID="Bac16" novelty="None" type="Bac"/><text>An example of a difference at the level of the gene structure is the insulin gene: in humans preproinsulin is encoded by a single gene (INS), while in mice two functional copies of the gene exist (Ins1 and Ins2).</text></s>
<s sid="23"><CoreSc1 advantage="None" conceptID="Mot5" novelty="None" type="Mot"/><text>Studies investigating transcriptional regulation of beta cell development in mice have, however, been successful in identifying pancreatic transcription factor genes important for human pancreatic development.</text></s>
<s sid="24"><CoreSc1 advantage="None" conceptID="Bac17" novelty="None" type="Bac"/><text>Much of the mouse work has involved the complete or targeted (conditional) knockout of a gene followed by detailed phenotypic studies during embryonic development and, when viable, in the resulting live offspring.</text></s>
<s sid="25"><CoreSc1 advantage="None" conceptID="Bac18" novelty="None" type="Bac"/><text>To date, mutations in eight different pancreatic transcription factor genes (PDX1, PTF1A, GLIS3, PAX6, RFX6, NEUROD1, NEUROG3, GATA6) have been identified in patients with neonatal diabetes (Lango Allen et al., 2012; Rubio-Cabezas et al., 2010, 2011; Sellick et al., 2004; Senée et al., 2006; Smith et al., 2010; Solomon et al., 2009; Stoffers et al., 1997).</text></s>
<s sid="26"><CoreSc1 advantage="None" conceptID="Bac19" novelty="None" type="Bac"/><text>For some transcription factor genes the genetic etiology in the patients was initially recognized from the similarity to the mouse phenotype (Rubio-Cabezas et al., 2010; Stoffers et al., 1997).</text></s>
<s sid="27"><CoreSc1 advantage="None" conceptID="Mot6" novelty="None" type="Mot"/><text>Mutations causing a pancreatic/diabetes phenotype have not been found in man for many pancreatic transcription factors important for rodent pancreatic development, but there have been no large, systematic studies of these genes in appropriate patients to date.</text></s>
<s sid="28"><CoreSc1 advantage="None" conceptID="Goa3" novelty="None" type="Goa"/><text>The aim of our study was to perform a comprehensive search for recessive mutations in genes encoding transcription factors known to be critical for pancreatic development in mice in a large collection of PNDM patients born to consanguineous parents.</text></s>
<s sid="29"><CoreSc1 advantage="None" conceptID="Met1" novelty="None" type="Met"/><text>Patients with consanguineous parents were chosen, as the likelihood of a recessive cause of their PNDM is greatly increased (Rubio-Cabezas et al., 2009), and all mouse models of transcription factors influencing pancreatic development involve biallelic inactivation.</text></s>
<s sid="30"><CoreSc1 advantage="None" conceptID="Obj1" novelty="None" type="Obj"/><text>We tested for mutations in homozygous regions encompassing known transcription factor genes independently of the clinical features to avoid the possible bias introduced when clinical features guide candidate gene testing.</text></s>
Results and Discussion
<s sid="31"><CoreSc1 advantage="None" conceptID="Obj2" novelty="None" type="Obj"/><text>We studied 147 patients from consanguineous pedigrees.</text></s>
<s sid="32"><CoreSc1 advantage="None" conceptID="Res1" novelty="None" type="Res"/><text>Mutations in non-transcription factor genes were identified in 110 probands (75%) (Table 1, Figure S1, and Table S1).</text></s>
<s sid="33"><CoreSc1 advantage="None" conceptID="Res2" novelty="None" type="Res"/><text>Systematic investigation of 29 transcription factor genes important for murine pancreatic development identified homozygous mutations in 7 genes in 12 patients from 11 families (30% of the undiagnosed probands or 7.5% of the entire cohort) (Table 1).</text></s>
<s sid="34"><CoreSc1 advantage="None" conceptID="Res3" novelty="None" type="Res"/><text>Overall, 106 out of 121 (88%) patients with a known genetic etiology had homozygous mutations, confirming that neonatal diabetes in the offspring of consanguineous families is usually recessive.</text></s>
<s sid="35"><CoreSc1 advantage="None" conceptID="Res4" novelty="None" type="Res"/><text>Homozygous Mutations in NKX2-2 Cause Neonatal Diabetes</text></s>
<s sid="36"><CoreSc1 advantage="None" conceptID="Res5" novelty="None" type="Res"/><text>Homozygous NKX2-2 nonsense or frameshift mutations were identified in three patients from two families (Table 2).</text></s>
<s sid="37"><CoreSc1 advantage="None" conceptID="Con1" novelty="None" type="Con"/><text>These mutations are highly likely to be pathogenic, as they are null mutations.</text></s>
<s sid="38"><CoreSc1 advantage="None" conceptID="Res6" novelty="None" type="Res"/><text>Cosegregation studies were consistent with recessive inheritance (Figure 1A).</text></s>
<s sid="39"><CoreSc1 advantage="None" conceptID="Res7" novelty="None" type="Res"/><text>No heterozygous or homozygous truncating mutations have been reported in 6,500 individuals sequenced by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/).</text></s>
<s sid="40"><CoreSc1 advantage="None" conceptID="Res8" novelty="None" type="Res"/><text>All three patients have severe defects in insulin secretion, as shown by intrauterine growth retardation (IUGR) and presentation of diabetes at an early age without features of pancreatic exocrine dysfunction (Table 2).</text></s>
<s sid="41"><CoreSc1 advantage="None" conceptID="Res9" novelty="None" type="Res"/><text>This is very similar to mice that are homozygous for a targeted disruption of Nkx2-2 and die shortly after birth with severe hyperglycemia (Briscoe et al., 1999; Sussel et al., 1998) (Table 2).</text></s>
<s sid="42"><CoreSc1 advantage="None" conceptID="Res10" novelty="None" type="Res"/><text>They have normal exocrine function, lack beta cells, and have fewer alpha and pancreatic polypeptide cells (Sussel et al., 1998).</text></s>
<s sid="43"><CoreSc1 advantage="None" conceptID="Res11" novelty="None" type="Res"/><text>The patients with homozygous null mutations in NKX2-2 also have severe developmental delay, which affects both motor and intellectual function as well as more specific features, such as hypotonia, cortical blindness, impaired visual tracking, and hearing impairment.</text></s>
<s sid="44"><CoreSc1 advantage="None" conceptID="Res12" novelty="None" type="Res"/><text>These are consistent with the severe neurological features seen in the Nkx2-2 knockout mouse (Table 2) and Nkx2-2 being essential for hindbrain development, ventral neuronal patterning, and oligodendrocyte differentiation (Briscoe et al., 1999; Qi et al., 2001).</text></s>
<s sid="45"><CoreSc1 advantage="None" conceptID="Res13" novelty="None" type="Res"/><text>Homozygous Mutations in MNX1 Cause Neonatal Diabetes</text></s>
<s sid="46"><CoreSc1 advantage="None" conceptID="Res14" novelty="None" type="Res"/><text>Two probands have homozygous missense mutations in MNX1 (previously described as HLXB9).</text></s>
<s sid="47"><CoreSc1 advantage="None" conceptID="Res15" novelty="None" type="Res"/><text>The p.F248L and p.F272L missense mutations are highly likely to be pathogenic, as they cosegregate with neonatal diabetes (Figure 1B), affect highly conserved residues within the homeodomain (Table 2, Figure 1C), are not listed in 6,500 individuals sequenced by the NHLBI Exome Sequencing Project, and in silico analysis predicted the mutations to be disease causing.</text></s>
<s sid="48"><CoreSc1 advantage="None" conceptID="Res16" novelty="None" type="Res"/><text>Our results are in line with the recently published paper by Bonnefond et al. (2013), who independently found the same MNX1 p.F272L mutation in proband 2.</text></s>
<s sid="49"><CoreSc1 advantage="None" conceptID="Res17" novelty="None" type="Res"/><text>Both probands in our study had severe intrauterine growth retardation and were diagnosed with diabetes in infancy without evidence of exocrine pancreatic dysfunction.</text></s>
<s sid="50"><CoreSc1 advantage="None" conceptID="Res18" novelty="None" type="Res"/><text>This is similar to the Mnx1 null mice that are born smaller than their wild-type littermates and have small islets and reduced numbers of beta cells and normal exocrine function (Table 2) (Harrison et al., 1999).</text></s>
<s sid="51"><CoreSc1 advantage="None" conceptID="Res19" novelty="None" type="Res"/><text>These mice also have dorsal lobe agenesis of the pancreas; it is not known if this is a feature of our two patients, as imaging and post mortem investigations were not performed.</text></s>
<s sid="52"><CoreSc1 advantage="None" conceptID="Obs1" novelty="None" type="Obs"/><text>Proband 1 (but not proband 2) had marked extrapancreatic developmental features, including severe neurological complications and hypoplastic lungs (respiratory failure caused death at 10 months) (Table 2).</text></s>
<s sid="53"><CoreSc1 advantage="None" conceptID="Res20" novelty="None" type="Res"/><text>In keeping with these observations, Mnx1 null mice have aberrant motor neuron differentiation but are difficult to study as they die at birth due to respiratory paralysis, which probably results from failure in the development of the phrenic nerve (Thaler et al., 1999).</text></s>
<s sid="54"><CoreSc1 advantage="None" conceptID="Con2" novelty="None" type="Con"/><text>The variability in phenotype between the two probands could be due to differences in the severity of their mutations, but further studies investigating the functional consequences of these missense mutations are required in order to explore this hypothesis.</text></s>
<s sid="55"><CoreSc1 advantage="None" conceptID="Bac20" novelty="None" type="Bac"/><text>Proband 1 also had sacral agenesis and a high imperforate anus, which are both cardinal features of Currarino syndrome (OMIM #176450), resulting from heterozygous MNX1 mutations (Currarino et al., 1981; Ross et al., 1998).</text></s>
<s sid="56"><CoreSc1 advantage="None" conceptID="Bac21" novelty="None" type="Bac"/><text>Mice homozygous for a null mutation do not have skeletal defects (Harrison et al., 1999).</text></s>
<s sid="57"><CoreSc1 advantage="None" conceptID="Bac22" novelty="None" type="Bac"/><text>Proband 2 and his heterozygous relatives do not have features of Currarino syndrome.</text></s>
<s sid="58"><CoreSc1 advantage="None" conceptID="Bac23" novelty="None" type="Bac"/><text>The highly variable phenotype is not unexpected, as around 50% of heterozygous carriers are clinically asymptomatic (Köchling et al., 2001).</text></s>
<s sid="59"><CoreSc1 advantage="None" conceptID="Res21" novelty="None" type="Res"/><text>As diabetes is not a feature of Currarino syndrome, it seems likely that a single copy of MNX1 is sufficient to maintain normal pancreatic development and glucose homeostasis, a hypothesis that is further supported by the observation that heterozygous mice have a normal pancreas (Harrison et al., 1999).</text></s>
<s sid="60"><CoreSc1 advantage="None" conceptID="Res22" novelty="None" type="Res"/><text>Known Causes of Neonatal Diabetes</text></s>
<s sid="61"><CoreSc1 advantage="None" conceptID="Res23" novelty="None" type="Res"/><text>Homozygous mutations in five pancreatic transcription factor genes previously reported to cause PNDM were identified in seven probands.</text></s>
<s sid="62"><CoreSc1 advantage="None" conceptID="Res24" novelty="None" type="Res"/><text>The phenotype of these patients is similar to that seen in mice with biallelic inactivation of these genes (Table 3).</text></s>
<s sid="63"><CoreSc1 advantage="None" conceptID="Bac24" novelty="None" type="Bac"/><text>Our two patients with GLIS3 mutations, the six previous cases (Dimitri et al., 2011; Senée et al., 2006), and the Glis3 mouse knockout (Watanabe et al., 2009) all have neonatal diabetes diagnosed in the first week of life and congenital hypothyroidism.</text></s>
<s sid="64"><CoreSc1 advantage="None" conceptID="Bac25" novelty="None" type="Bac"/><text>We identified one patient with a homozygous NEUROD1 mutation.</text></s>
<s sid="65"><CoreSc1 advantage="None" conceptID="Bac26" novelty="None" type="Bac"/><text>Both this patient and a previously reported case from a nonconsanguineous pedigree (Rubio-Cabezas et al., 2010) have neonatal diabetes, neurodevelopmental delay, cerebellar hypoplasia, and hearing and visual impairment.</text></s>
<s sid="66"><CoreSc1 advantage="None" conceptID="Bac27" novelty="None" type="Bac"/><text>The Neurod1 null mouse also has neonatal diabetes and severe neurological defects, including impaired coordination and ataxia, cerebellar hypoplasia, sensorineural deafness, and retinal blindness (Liu et al., 2000; Miyata et al., 1999; Morrow et al., 1999; Naya et al., 1997; Pennesi et al., 2003).</text></s>
<s sid="67"><CoreSc1 advantage="None" conceptID="Res25" novelty="None" type="Res"/><text>The proband with a homozygous RFX6 mutation was diagnosed with diabetes at 8 days and had duodenal atresia and gall bladder agenesis.</text></s>
<s sid="68"><CoreSc1 advantage="None" conceptID="Res26" novelty="None" type="Res"/><text>This is consistent with the previous five cases and the Rfx6 knockout mouse, which has neonatal diabetes and small bowel atresia (Smith et al., 2010).</text></s>
<s sid="69"><CoreSc1 advantage="None" conceptID="Res27" novelty="None" type="Res"/><text>Two probands with homozygous PDX1 (previously described as IPF1) missense mutations had isolated PNDM.</text></s>
<s sid="70"><CoreSc1 advantage="None" conceptID="Res28" novelty="None" type="Res"/><text>In both man and mouse, the severity of the PDX1 mutation determines the pancreatic phenotype.</text></s>
<s sid="71"><CoreSc1 advantage="None" conceptID="Bac28" novelty="None" type="Bac"/><text>Pancreatic agenesis was seen in the mouse knockout (Jonsson et al., 1994) and in patients with two copies of a severe mutation (Fajans et al., 2010; Schwitzgebel et al., 2003; Stoffers et al., 1997, 1998; Thomas et al., 2009).</text></s>
<s sid="72"><CoreSc1 advantage="None" conceptID="Bac29" novelty="None" type="Bac"/><text>In mice, hypomorphic mutations are associated with diabetes without evidence of exocrine deficiency (Oliver-Krasinski et al., 2009); we and others have shown that patients with less-severe homozygous missense mutations have neonatal diabetes with normal or mildly impaired exocrine function (De Franco et al., 2013; Nicolino et al., 2010).</text></s>
<s sid="73"><CoreSc1 advantage="None" conceptID="Res29" novelty="None" type="Res"/><text>An intronic PTF1A mutation (c.784 + 4A &gt; G) was identified in a proband with pancreatic agenesis.</text></s>
<s sid="74"><CoreSc1 advantage="None" conceptID="Res30" novelty="None" type="Res"/><text>This mutation is predicted to result in an alternative splice donor site (Alamut Interactive Biosoftware, version 2.1) and the inclusion of an additional 4 bases in the mRNA, causing a frameshift and premature termination codon at residue 271.</text></s>
<s sid="75"><CoreSc1 advantage="None" conceptID="Res31" novelty="None" type="Res"/><text>The pancreatic phenotype is similar to the three previously reported patients with nonsense or frameshift mutations and the Ptf1a null mouse (Al-Shammari et al., 2011; Krapp et al., 1998; Sellick et al., 2004).</text></s>
<s sid="76"><CoreSc1 advantage="None" conceptID="Res32" novelty="None" type="Res"/><text>Our patient has mild learning difficulties at 15 years old, which is in contrast to the other patients who had severe neurological features, causing death before 4 months of age.</text></s>
<s sid="77"><CoreSc1 advantage="None" conceptID="Res33" novelty="None" type="Res"/><text>These patients and the knockout mouse had cerebellar aplasia.</text></s>
<s sid="78"><CoreSc1 advantage="None" conceptID="Res34" novelty="None" type="Res"/><text>In a mouse model, reduced Ptf1a gene dosage results in pancreatic hypoplasia and glucose intolerance in a dose-dependent manner (Fukuda et al., 2008).</text></s>
<s sid="79"><CoreSc1 advantage="None" conceptID="Con3" novelty="None" type="Con"/><text>We hypothesize that the absence of cerebellar agenesis in this patient may reflect a reduced functional severity of the splicing mutation compared to previously reported null mutations.</text></s>
<s sid="80"><CoreSc1 advantage="None" conceptID="Con4" novelty="None" type="Con"/><text>The finding that mutations in NKX2-2 and MNX1 can cause neonatal diabetes takes the number of genes in which mutations are known to cause PNDM from 18 to 20, of which 10 encode pancreatic transcription factors.</text></s>
<s sid="81"><CoreSc1 advantage="None" conceptID="Con5" novelty="None" type="Con"/><text>Unlike previous studies, which have identified mutations in humans because of similarities in phenotype with the null mouse, our systematic approach guided by areas of linkage has allowed us to screen all transcription factor genes independently of clinical features.</text></s>
<s sid="82"><CoreSc1 advantage="None" conceptID="Con6" novelty="None" type="Con"/><text>Our results confirm that the consequence of inactivation of pancreatic transcription factor genes in humans is similar to the phenotype observed in knockout mice.</text></s>
<s sid="83"><CoreSc1 advantage="None" conceptID="Res35" novelty="None" type="Res"/><text>This is in contrast to heterozygous loss-of-function mutations where differences in phenotype have been observed.</text></s>
<s sid="84"><CoreSc1 advantage="None" conceptID="Bac30" novelty="None" type="Bac"/><text>For example, monoallelic mutations in GATA6 or HNF1B cause pancreatic agenesis with congenital heart defects or renal cysts with diabetes, respectively, while mice heterozygous for a null mutation in Gata6 or Hnf1b show no obvious phenotype (Bingham et al., 2001; Haumaitre et al., 2005; Lango Allen et al., 2012; Morrisey et al., 1998).</text></s>
<s sid="85"><CoreSc1 advantage="None" conceptID="Bac31" novelty="None" type="Bac"/><text>There are some limitations to our study.</text></s>
<s sid="86"><CoreSc1 advantage="None" conceptID="Res36" novelty="None" type="Res"/><text>The minimum prevalence of transcription factor mutations in our cohort of patients with consanguineous PNDM was 7.5%, but the true prevalence may be slightly higher since heterozygous or compound heterozygous mutations would have been missed as a result of the study design.</text></s>
<s sid="87"><CoreSc1 advantage="None" conceptID="Con7" novelty="None" type="Con"/><text>However, as all of the patients were known to be consanguineous, the prior probability is that they have recessively inherited disease due to a homozygous mutation.</text></s>
<s sid="88"><CoreSc1 advantage="None" conceptID="Con8" novelty="None" type="Con"/><text>While the identification of patients with homozygous inactivating mutations in pancreatic transcription factor genes has confirmed their role in human organogenesis, these findings can only provide limited information on pancreatic development, as detailed physiological studies in man are not always possible.</text></s>
<s sid="89"><CoreSc1 advantage="None" conceptID="Con9" novelty="None" type="Con"/><text>This is especially true for the patients within our cohort with NKX2-2 and MNX1 mutations that are all currently under 13 years of age and, for those with NKX2-2 mutations, have severe developmental delay, which means that in-depth studies on pancreatic and neurological function are not possible.</text></s>
<s sid="90"><CoreSc1 advantage="None" conceptID="Con10" novelty="None" type="Con"/><text>In conclusion, we have shown that mutations in NKX2-2 and MNX1 cause neonatal diabetes.</text></s>
<s sid="91"><CoreSc1 advantage="None" conceptID="Con11" novelty="None" type="Con"/><text>This confirms a key role for NKX2-2 and MNX1 in human pancreatic development.</text></s>
<s sid="92"><CoreSc1 advantage="None" conceptID="Con12" novelty="None" type="Con"/><text>Comparisons of phenotypes observed in humans and mice with inactivation of transcription factor genes supports common steps critical for pancreatic development.</text></s>
<s sid="93"><CoreSc1 advantage="None" conceptID="Con13" novelty="None" type="Con"/><text>This study validates the use of knockout mice for understanding beta cell development in humans.</text></s>
Experimental Procedures
Cohort
<s sid="94"><CoreSc1 advantage="None" conceptID="Con14" novelty="None" type="Con"/><text>We recruited 147 patients from consanguineous pedigrees (parents of the proband were second cousins or more closely related) who were diagnosed with permanent diabetes before 6 months of age or were diagnosed with permanent diabetes before 9 months and had any additional clinical features that made a diagnosis of type 1 diabetes less likely.</text></s>
<s sid="95"><CoreSc1 advantage="None" conceptID="Con15" novelty="None" type="Con"/><text>Informed consent was obtained from all participants or their parents, and institutional review board approval was received for this study.</text></s>
<s sid="96"><CoreSc1 advantage="None" conceptID="Con16" novelty="None" type="Con"/><text>Exclusion of Nontranscription Factor Mutations in PNDM</text></s>
<s sid="97"><CoreSc1 advantage="None" conceptID="Con17" novelty="None" type="Con"/><text>To detect mutations in non-transcription factor genes that cause PNDM, we used Sanger sequencing (ABCC8, KCNJ11, INS) in all patients, followed by homozygosity mapping with sequencing of known genes (EIF2AK3, IER3IP1, GCK, SLC19A2, and SLC2A2) within homozygous regions &gt;3 Mb.</text></s>
<s sid="98"><CoreSc1 advantage="None" conceptID="Con18" novelty="None" type="Con"/><text>Detecting Mutations of Pancreatic Transcription Factor Genes</text></s>
<s sid="99"><CoreSc1 advantage="None" conceptID="Con19" novelty="None" type="Con"/><text>From published literature, we identified 29 transcription factor genes crucial for murine pancreatic development (Seymour and Sander, 2011; Zaret and Grompe, 2008) (Table 1).</text></s>
<s sid="100"><CoreSc1 advantage="None" conceptID="Con20" novelty="None" type="Con"/><text>We identified homozygous regions through genome-wide single nucleotide polymorphism (SNP) genotyping and used Sanger sequencing to detect mutations within homozygous regions encompassing these genes.</text></s>
<s sid="101"><CoreSc1 advantage="None" conceptID="Con21" novelty="None" type="Con"/><text>Genome-wide SNP Analysis to Localize Etiological Genes by Linkage</text></s>
<s sid="102"><CoreSc1 advantage="None" conceptID="Con22" novelty="None" type="Con"/><text>Genotyping was undertaken on the Affymetrix 10K, 500K, or v6.0 SNP chips by Medical Solutions, ALMAC Diagnostics, or AROS Applied Biotechnology.</text></s>
<s sid="103"><CoreSc1 advantage="None" conceptID="Con23" novelty="None" type="Con"/><text>Processing of genomic DNA was performed as per the Affymetrix protocol, and in-house Perl scripts were developed to identify regions of significant homozygosity (&gt;3 Mb) as previously described (Flanagan et al., 2011).</text></s>
<s sid="104"><CoreSc1 advantage="None" conceptID="Con24" novelty="None" type="Con"/><text>Sequencing of Pancreatic Transcription Factor Genes</text></s>
<s sid="105"><CoreSc1 advantage="None" conceptID="Res37" novelty="None" type="Res"/><text>When a large homozygous region encompassing one of the pancreatic transcription factor genes was identified, the coding regions and intron and exon boundaries of the gene were sequenced (Table 1, Figure S1, and Tables S2 and S3).</text></s>
<s sid="106"><CoreSc1 advantage="None" conceptID="Con25" novelty="None" type="Con"/><text>Details of PCR primers and sequencing conditions are available on request.</text></s>
<s sid="107"><CoreSc1 advantage="None" conceptID="Con26" novelty="None" type="Con"/><text>Pathogenicity was assessed on the basis of the characteristics of the mutation, the conservation of the affected amino acid, the absence from variant databases (accessed using Alamut v.2 Interactive Biosoftware), and cosegregation within families.</text></s>
Patient Phenotype Assessment
<s sid="108"><CoreSc1 advantage="None" conceptID="Con27" novelty="None" type="Con"/><text>For patients with homozygous mutations, their phenotype (both pancreatic and extrapancreatic) was compared with the phenotype of the knockout mouse for the same gene.</text></s>
</BODY>
<OTHER>
Acknowledgments
The authors thank Annet Damhuis for technical assistance.
O.R.-C. holds a &quot;Miguel Servet&quot; Research Fellowship funded by the Instituto de Salud Carlos III (CP11/00263).
A.T.H. and S.E. are both employed as core members of the Exeter NIHR Clinical Research Facility.
A.T.H. is an NIHR Senior Investigator.
This work was funded by the Wellcome Trust (098395/Z/12/Z), Diabetes UK, and the European Community's Seventh Framework Programme (FP7/2007-2013), grant agreement number FP7-PEOPLE-ITN-2008 (Marie Curie ITN, BOLD).
The authors declare no conflict of interest.
Supplemental Information
Supplemental Information includes one figure and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.cmet.2013.11.021.
Supplemental Information
Document S1.
Figure S1 and Tables S1-S3

</OTHER>
</PAPER>